SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE
申请人:Amgen Inc.
公开号:EP1448564A2
公开(公告)日:2004-08-25
US6921762B2
申请人:——
公开号:US6921762B2
公开(公告)日:2005-07-26
[EN] SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSES DE TYPE INDOLIZINE SUBSTITUES ET LEURS METHODES D'UTILISATION
申请人:AMGEN INC
公开号:WO2003044021A2
公开(公告)日:2003-05-30
Selected novel substituted indolizine-like compounds are effective for treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Substituted indolizine-like compounds and methods of use
申请人:——
公开号:US20030195221A1
公开(公告)日:2003-10-16
Selected novel substituted indolizine-like compounds are effective for treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.